Balancing benefit and risk in early Alzheimer's disease: the European Medicines Agency (EMA) assessment of lecanemab and donanemab
Author:
Lorenzo Guizzaro,Ewa Bałkowiec-Iskra,Marion Haberkamp,Peter G.M. Mol,Alexandre Moreau,Jan Mueller-Berghaus,Daniela Philadelphy,Pavel Balabanov,Juan Garcia,Steffen Thirstrup,Bruno Sepodes
Publication:
The Lancet Regional Health - Europe
© 2026 The Author(s). Published by Elsevier Ltd.